Amryt Pharma is a biopharmaceutical company focused on acquiring, developing, and commercializing treatments for patients with rare and orphan diseases. It provides replacement therapy to treat the complications of leptin deficiency, long-term maintenance therapy for acromegaly patients, and adjunct for adults with Homozygous familial Hypercholesteraemia. Amryt's development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa and pre-clinical gene therapy for patients with dystrophic EB.